[ Ana Sayfa | Amaç ve Kapsam | Yayın Kurulu | İçindekiler | Arşiv | Yayın Arama | Yazım Kuralları | İletişim ]
Ege Journal of Medicine
2019, Cilt 58, Sayı 1, Sayfa(lar) 052-054
[ Türkçe Özet ] [ Tam Metin ] [ PDF ] [ Benzer Makaleler ]
Continuous flow ventricular assist device implantation in pediatrics: Single center experience
Pelin Öztürk, Osman Nuri Tuncer
Ege University Faculty of Medicine, Department of Cardiovascular Surgery, İzmir, Turkey
Keywords: Pediatric, heart failure, ventricular assist device

Aim: Heart transplantation is the gold standard of treatment for patients with medical therapy resistant end-stage heart failure. Particularly in the pediatric age group use of ventricular asist device (VAD) is mandatory, due to donor organ limitation and prolonged waiting lists.

Materials and Methods: This retrospective review of fourteen patients under 19 years of age who underwent continuous flow left VAD implantation between August 2012 and March 2018. All patients have met the criteria for heart transplantation. HeartWare (HeartWare Inc. Medtronic) HVAD was implanted to all patients.

Results: There were eight girls and six boys with a mean overall age of 15.4 (minimum11-maximum 18) years and mean body weight of 42.4 kg and body surface area (BSA) is 1.4 kg/cm². The mean follow-up was 549 days. Survival rate at six months was 90%. Six patients (42.9%) are still waiting for transplantation on VAD support. Six patients (42.9%) underwent heart transplantation successfully. Two patients died while they were waiting for transplantation on device support.

Conclusion: The use of continuous flow ventricular assist devices became more popular because reduced dimensions along with technological advances. In this article, we wanted to share our experience about continuous flow ventricular assist device implantation as bridge to transplantation in pediatric patients.


[ Türkçe Özet ] [ Tam Metin ] [ PDF ] [ Benzer Makaleler ]